Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 2. metabolism and elimination

Journal of Psychiatric Practice

Volumn 18, Issue 5, 2012, Pages 361-368

  Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

atypical antipsychotics; cytochrome P450 enzymes; drugdrug interactions; metabolism; pharmacokinetics

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; FLUOXETINE; ILOPERIDONE; KETOCONAZOLE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PAROXETINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADVERSE OUTCOME; AEROBIC METABOLISM; ARTICLE; COPY NUMBER VARIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG SPECIFICITY; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY INJURY; KIDNEY TUBULE EXCRETION; LIVER INJURY; NONHUMAN; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; HUMANS;

EID: 84866864909     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000419820.68128.ad     Document Type: Article

References (24)

1. Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 1. J Psychiatr Pract 2012;18:199-204.
2. Abilify (aripiprazole) prescribing information, February 2012, Bristo-Meyers Squibb and Otsuka Pharmaceutical (available at www.abilify.com, accessed May 4, 2012).
3. Saphris (asenapine) prescribing information, October 2011, Merck and Company (available at hcp.saphris.com /asenapine/saphris/hcp/default.jsp, accessed May 4, 2012).
4. Clozaril (clozapine) prescribing information, October 2011, Novartis Pharmaceuticals (available at www.pharma.us.novartis .com/product/pi/pdf/ Clozaril.pdf, accessed May 4, 2012).
5. Fanapt (iloperidone) prescribing information, January 2012, Novartis Pharmaceuticals (available at www.pharma. us.novartis.com/product/pi/pdf/fanapt. pdf, accessed May 4, 2012).
6. Latuda [lurasidone] prescribing information, April 2012, Sunovion Pharmaceuticals (available at www.latuda.com /LatudaPrescribingInformation.pdf, accessed May 3, 2012).
7. Zyprexa (olanzapine) prescribing information, June 2011, Eli Lilly (available at pi.lilly.com/us/zyprexa-pi.pdf, accessed May 4, 2012).
8. Invega (paliperidone) prescribing information, September 2011, Janssen Pharmaceuticals (available at www.invegasustenna. com/important-product- information, accessed May 4, 2012).
9. Seroquel (quetiapine) prescribing information, February 2012, AstraZeneca Pharmaceuticals (available at www1 .astrazeneca-us.com/pi/Seroquel.pdf, accessed May 4, 2012).
10. Risperdol (risperidone) prescribing information, Septem ber 2011, Janssen Pharmaceuticals (available at www .risperdal.com/prescribing.html, accessed May 4, 2012).
11. Geodon (ziprasidone) prescribing information, December 2010, Pfizer (available at labeling.pfizer.com/Show-Labeling .aspx?id=584, accessed May 4, 2012).
12. U.S. Food and Drug Administration. Drugs@FDA instructions: Health:information (available at www.fda.gov/Drugs/ InformationOnDrugs/ ucm079450.htm, accessed August 30, 2012).
13. Preskorn SH. Columns on dose response (available at www.preskorn.com/ column3.html, accessed August 27, 2012).
14. Preskorn SH. Outliers on the dose-response curve: How to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry. J Psychiatr Pract 2010;16:177-82.
15. Preskorn SH. Patients who do not respond to the "usual" dose: Why Terry fell off the dose-response curve. J Psychiatr Pract 2009;15:460-6.
16. Preskorn SH. Practical application of therapeutic drug monitoring: A tale of two patients. J Psychiatr Pract 2008;14:301-6.
17. Preskorn SH. Flat dose-response curves for efficacy: What do they mean to the clinician? J Psychiatr Pract 2008;14: 232-6.
18. Preskorn SH. Why are CYP enzymes important when considering SSRIs? In: Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, OK: Professional Communications; 1996 (available at www.preskorn.com /books/ssri-s7.html, accessed August 30, 2012).
19. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36:769-79.
20. Sheehan JJ, Sliwa JK, Amatniek JC, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab 2010;11:516-25.
21. Flockhart DA. Drug interactions: Cytochrome P450 drug interaction table. Indiana University School of Medicine, 2007 (available at medicine.iupui.edu/ clinpharm/ddis /table.aspx, accessed August 30, 2012).
22. Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: Role of therapeutic drug monitoring. J Psychiatr Pract 2005;11:1-13.
23. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997;42:1-5.
24. Olincy A, Stevens KE. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol 2007;74:1192-1201.